Examines Sal B's role in reducing neuronal injury and excitotoxicity in ischemic conditions, indicating potential therapeutic implications.
BACKGROUND/AIM: models of ischemic injury to investigate whether Sal B attenuated excitotoxic neuronal damage. MATERIALS AND METHODS: ) to induce hypoxia-like injury, after which neuronal viability and apoptotic markers were evaluated. A middle cerebral artery occlusion (MCAO) rat model was constructed to examine the ischemia-induced alterations in excitatory neurotransmission-related proteins. Protein expression was analyzed using western blotting and immunofluorescence, while gene expression was assessed using quantitative real-time PCR. RESULTS: -induced apoptotic signaling, as indicated by the decreased cleavage of caspase-3 and PARP-1. In the MCAO model, ischemia altered the expression of glutamatergic markers, including glutamate receptor-1 (GluA1), vesicular glutamate transporter-2 (VGLUT2), and N-methyl-D-aspartate receptor-1 (NMDAR1). Sal-B treatment attenuated these alterations, reducing the GluA1 and VGLUT2 intensities in NeuN-positive cortical neurons. Furthermore, Sal B decreased mRNA expression of the hypoxia marker HIF1α and the pro-apoptotic factor Noxa, while increasing expression of the anti-apoptotic Bcl2 family members, Bcl-2 and Bcl-xL. CONCLUSION: SalB attenuates hypoxia- and ischemia-induced neuronal injury and modulates excitatory neurotransmission in the ischemic cortex. These findings indicate that Sal B exerts neuroprotective effects partly through the regulation of excitatory synaptic signaling following cerebral ischemia.
No takes yet. Share an insight, caveat, or question.
Park et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: